About Protagenic Therapeutics (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.
Industry, Sector and Symbol
Industry Networking & Communication Devices
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book7.33
Return on Equity-104.22%
Return on Assets-80.68%
Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions
What is Protagenic Therapeutics' stock symbol?
Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."
How were Protagenic Therapeutics' earnings last quarter?
When will Protagenic Therapeutics make its next earnings announcement?
Who are some of Protagenic Therapeutics' key competitors?
Some companies that are related to Protagenic Therapeutics include Pain Therapeutics (PTIE), Caladrius Biosciences (CLBS), Catabasis Pharmaceuticals (CATB), BioSig Technologies (BSGM), Proteon Therapeutics (PRTO), Chiasma (CHMA), TRACON Pharmaceuticals (TCON), Cleveland BioLabs (CBLI), Imprimis Pharmaceuticals (IMMY), Streamline Health Solutions (STRM), Concordia International (CXRX), OvaScience (OVAS), Rewalk Robotics (RWLK), Anthera Pharmaceuticals (ANTH), Soleno Therapeutics (SLNO), AzurRx BioPharma (AZRX), Evoke Pharma (EVOK) and Microbot Medical (MBOT).
Who are Protagenic Therapeutics' key executives?
Protagenic Therapeutics' management team includes the folowing people:
- Garo H. Armen Ph.D., Chairman of the Board (Age 64)
- Alexander K. J. Arrow M.D., Acting Chief Financial Officer (Age 47)
- Joshua N. Silverman, Director (Age 46)
- Robert Burton Stein, Director (Age 66)
- Khalil Z. Barrage, Independent Director (Age 51)
- Brian Corvese, Independent Director
How do I buy Protagenic Therapeutics stock?
Shares of Protagenic Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protagenic Therapeutics' stock price today?
One share of Protagenic Therapeutics stock can currently be purchased for approximately $1.76.
How big of a company is Protagenic Therapeutics?
Protagenic Therapeutics has a market capitalization of $20.52 million. Protagenic Therapeutics employs 3 workers across the globe.
How can I contact Protagenic Therapeutics?
Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected]
MarketBeat Community Rating for Protagenic Therapeutics (PTIX)MarketBeat's community ratings are surveys of what our community members think about Protagenic Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Protagenic Therapeutics (OTCMKTS:PTIX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Protagenic Therapeutics (OTCMKTS:PTIX) Earnings History and Estimates Chart
Protagenic Therapeutics (OTCMKTS PTIX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/17/2018|| || || || || || || || |
|11/7/2013||Q313||$0.07||$4.70 million||$7.30 million||View||N/A|
|8/8/2013||Q2 2013||$0.06||$5.00 million||$7.10 million||View||N/A|
|11/8/2012||Q312||($0.12)||$9.00 million||$4.70 million||View||N/A|
Protagenic Therapeutics (OTCMKTS:PTIX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Protagenic Therapeutics (OTCMKTS:PTIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Protagenic Therapeutics (OTCMKTS PTIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 42.00%
Protagenic Therapeutics (OTCMKTS PTIX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/28/2013||Quaker Capital Management Corp||Major Shareholder||Sell||100,000||$1.25||$125,000.00|| |
Protagenic Therapeutics (OTCMKTS PTIX) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Protagenic Therapeutics (OTCMKTS:PTIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Protagenic Therapeutics (OTCMKTS:PTIX) Income Statement, Balance Sheet and Cash Flow Statement
Protagenic Therapeutics (OTCMKTS PTIX) Stock Chart for Sunday, February, 25, 2018